Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm

Affiliations

¹ Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: vickersa@mskcc.org.
² Department of Urology, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
³ Section of Urology, Department of Surgery, The University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.

Editorial

Andrew J Vickers et al. Eur Urol. 2023 Apr.

. 2023 Apr;83(4):304-306.

doi: 10.1016/j.eururo.2022.10.001. Epub 2022 Oct 21.

¹ Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: vickersa@mskcc.org.
² Department of Urology, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
³ Section of Urology, Department of Surgery, The University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.

No abstract available

Comment on

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.
Netto GJ, Amin MB, Compérat EM, Gill AJ, Hartmann A, Moch H, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Berney DM. Netto GJ, et al. Eur Urol. 2023 Apr;83(4):301-303. doi: 10.1016/j.eururo.2022.09.015. Epub 2022 Oct 4. Eur Urol. 2023. PMID: 36202687